



Attorney Docket No.: FREE.P-001-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrade et al.  
Serial No.: 10/616,682  
Filed: 07/09/2003  
Confirmation: 2574  
Title: Regulation of Human Pluripotential Cells by Bone Morphogenetic Protein 2 Antagonists

**SUBMISSION OF INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant requests that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith. No fee is believed to be due with this paper as we have not received an action on the merits. However, the Commissioner is authorized to charge any additional fees which might be due to Deposit Account No. 15-0610.

Respectfully submitted,  
OPPEDAHL & LARSON LLP

*Marina Larson*

Marina T. Larson, Ph.D.  
Reg. No. 32,038  
P.O. Box 5068  
Dillon, CO 80435-5068  
Ph.: 970-468-6600  
Fax: 970-468-0104


**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)**

I hereby certify that this paper and the attachments mentioned herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

February 5, 2004

Anne Wagner  
Anne Wagner

February 5, 2004  
Date of Signature



PTO/SB/08A (06-03)

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/616,682
				Filing Date	7/9/2003
				First Named Inventor	Andrade et al.
				Art Unit	1632
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	FREE.P-001-2

## **U.S. PATENT DOCUMENTS**


## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	10/616,682
Filing Date	7/9/2003
First Named Inventor	Andrade et al.
Art Unit	1632
Examiner Name	
Attorney Docket Number	FREE.P-001-2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BREHM ET AL., Oct-4: more than just a POUerful marker of the mammalian germline?, APMIS, 1998, Page(s) 114-126, Volume 106	
		COUCOUVANIS ET AL., BMP signaling plays a role in visceral endoderm differentiation and cavitation in the early mouse embryo, Development, 1999, Page(s) 535-546, Volume 126	
		HEATH, Experimental analysis of teratocarcinoma cell multiplication and purification of embryonal carcinoma-derived growth fact, Teratocarcinomas and embryonic stem cells, 1987, Page(s) 183-206	
		HERSZFELD ET AL., Regulation of Human Pluripotent Stem Cell Differentiation by Bone Morphogenetic Protein-2, 1999, Poster presented at Combio 99, Gold Coast, Australia, Page(s) 1	
		LATZA ET AL., CD30 Antigen in Embryonal Carcinoma and Embryogenesis and Release of the Soluble Molecule, American Journal of Pathology, 2/1/1995, Volume 146, Number 2	
		PERA ET AL., Cultured Stem-Cells from Human Testicular Teratomas: The Nature of Human Embryonal Carcinoma, and its comparison with Two Types of Yolk-Sac Carcinoma, International Journal of Cancer, 1987, Page(s) 334-343, Volume 40	
		PERA ET AL., Isolation and characterization of a multipotent clone of human embryonal carcinoma cells, Differentiation, 1989, Page(s) 10-23, Volume 42	
		PERA ET AL., Expression of CD30 and CD30 Ligand in Cultured Cell Lines from Human Germ-Cell Tumors, Laboratory Investigation, 1997, Page(s) 497-504, Volume 76, Number 4	
		PERA ET AL., Differentiation of human pluripotent teratocarcinoma stem cells induced by bone morphogenetic protein-2, Reproduction of Development, 1998, Page(s) 551-555, Volume 10	
		ROACH ET AL., Cultured Cell Lines from Human Teratomas: Windows into Tumour Growth and Differentiation and Early Human Development, Eur Urol, 1993; Page(s) 82-88, Volume 23	
		ROACH ET AL., Hepatocytic Transcription Factor Expression in HUMAN Embryonal Carcinoma and Yolk Sac Carcinoma Cell Lines: Expression of HNF-3 $\alpha$ in Models of Early Endodermal Cell Differentiation, Experimental Cell Research, 1994, Page(s) 189-198, Volume 215	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.